British Journal of Renal Medicine - 2015


Comment: Salt to taste
John Bradley
pp 59-59
For many years, the four basic tastes were considered to be sweetness, sourness, bitterness and saltiness. The Japanese have recognised a savoury taste, called umami, for over 100 years, but it was not widely accepted as the fifth basic taste until after the 1st International Symposium on Umami Taste in Hawaii in 1985. Taste buds in the mouth and throat process and integrate these tastes to determine whether they are perceived as pleasant or unpleasant.
Preventing acute kidney injury recurrence: do we warn patients about nephrotoxic medications?
James McGuinness, Oliver Lloyd, Jennifer Hind, Sian Finlay and Thalakunte Muniraju
pp 60-62
Acute kidney injury (AKI) is common, serious and expensive, with even small rises in serum creatinine having measurable adverse effects on patient outcomes, including mortality and length of hospital stay. Strikingly, there is evidence that many cases of AKI may be preventable. A 2009 National Confidential Enquiry into Patient Outcome and Death report found that 21% of patients who died of hospital-acquired AKI had both predicable and avoidable risk factors. Stevens et al identified an iatrogenic component in 34% of AKI cases, with 18.4% being preventable. The majority of these cases were due to adverse effects of medication.
Familial hyperaldosteronism: the clinical and genetic picture
Gema Souto-Adeva, María M Adeva-Andany, Alberto Domínguez-Montero, Paraskevi Xekouki and Constantine A Stratakis
pp 63-67
Primary aldosteronism is one of the most frequent causes of potentially curable systemic hypertension and can be ameliorated by surgical or pharmacological intervention. Early detection is crucial in order to avoid life threatening cardiovascular events, including stroke, acute coronary syndromes and atrial fibrillation. In addition, primary aldosteronism is associated with abnormal glucose metabolism and may induce maternal and fetal morbidity during pregnancy.
Bookshelf: Clinical Companion in Nephrology
Donal J O’Donoghue
pp 68-68
Mark Findlay and Christopher Isles have written a refreshingly concise primer in renal medicine. It is easy to read and logically organised, and it uses real-world cases to raise and answer clinically relevant questions.
What I tell my patients about interdialytic weight gain
Elizabeth J Lindley, Claire Gardiner, David Keane and Mark Wright
pp 69-71
Although you may sometimes put on ‘real’ weight (that is, flesh weight) between dialysis sessions, especially after a bout of illness, interdialytic weight gain (IDWG) is usually due to the accumulation of fluid. This article is about managing interdialytic fluid gain (IDFG). As long as you do not gain or lose real weight, your IDWG in kilograms will be the same as your IDFG in litres.
Dialysis commissioning: time for the kidney community to seize the initiative
Fiona Loud
pp 72-72
In October 2014, the kidney community was informed by NHS England that it intended to devolve dialysis services to clinical commissioning groups (CCGs). Initially, no consultation was planned and it was intended that the new model be implemented from April 2015. NHS England did not provide a clear explanation for the basis of its proposed changes, nor did it explain the expected improvements or the rationale for implementation within such a short period of time. The approach of devolving res-ponsibility for dialysis to CCGs was inconsistent with the commissioning of kidney transplantation, which would remain a specialised service, despite being part of the same care pathway for people with kidney failure.
Cystinuria: an inherited genetic disorder that breaks the rules
John Sayer and Richard Coward
pp 73-75
A Kidney Research UK-funded research fellow, Dr Hannah Rhodes, working in a collaboration between Bristol University and Newcastle University, has provided important insights into the complexities of the rare inherited renal stone disease cystinuria. The typical textbook descriptions of this severe condition are often incomplete. The molecular genetics of cystinuria and the clinical phenotypes associated with different forms of the condition have been clarified. Here we report the inheritance patterns and clinical outcomes, including surgical procedures and end-stage renal disease, in a UK cohort of patients with cystinuria.
Powerful People
Donal J O’Donoghue
pp 77-77
For decades, policy-makers have focused on structural and organisational changes as the primary means of driving improvement. Our NHS is still coming to terms with the new architecture introduced by the most recent reorganisation in 2013. Although, to be fair, the quality, productivity and sustainability challenge has been well articulated in The Five Year Forward View. Other levers for change – competition, transparency, incentives – have been deployed with some success. In these austere times, competition has given way to collaboration, and incentives often seem perverse, rather than facilitating the improvement they are designed to achieve. But a key catalyst for change has been missed: patient power.
Ocular complications of anti-glomerular basement membrane disease
Jacqueline Nevols, Nishanthan Srikantha, Kunal K Dansingani and David Farnworth
pp 79-81
Anti-glomerular basement membrane (anti-GBM) disease is an immune-complex-mediated small-vessel vasculitis predominantly affecting the kidneys and lungs. Anti-GBM disease is rare, with an incidence of 0.5–1 cases per million per year. Autoantibodies are targeted against certain epitopes of type IV collagen, the dominant collagen found in glomerular and alveolar basement membranes. This particular type of collagen is also found in various ocular structures, but case reports of eye disease associated with anti-GBM disease are rare.

The British Journal of Renal Medicine was previously supported by Baxter Healthcare from 2011 to 2013, by Sandoz in 2011, by Shire Pharmaceuticals from 2006 to 2011, by Ortho Biotech and Shire Pharmaceuticals in 2005, by Ortho Biotech from 2000 to 2005 and by Janssen Cilag from 1996 to 2000.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly, the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title British Journal of Renal Medicine is the property of Hayward Group Ltd and, together with the content, is bound by copyright. Copyright © 2017 Hayward Group Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1365-5604 (Print)  ISSN 2045-7839 (Online)